Advance Solid Tumors clinical trials

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

CS2009 for advanced solid tumors

This trial tests a new drug called CS2009 for people with advanced solid tumors that haven't responded to other treatments. It aims to see if the drug is safe and effective.

HS-20117-2 Injection in Patients With Advanced Solid Tumors

Custom immune cell therapy for advanced solid tumors

This study tests a new treatment that uses your own immune cells, called TIL, to fight advanced solid tumors. It may be given alone or with another drug that helps the immune system attack cancer. The goal is to see if this treatment is safe and effective for people who have already tried other treatments.

Study of a new drug for advanced solid tumors with a specific genetic feature

This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.

Combination of two study drugs for advanced pancreatic and other solid tumors

This trial tests two drugs, ulixertinib and palbociclib, taken together to see if they can shrink tumors in patients with advanced pancreatic cancer, melanoma, or other solid tumors. It may be an option for people who have already tried standard treatments.

Study of a new drug for advanced solid tumors

This trial tests a new drug, BG-75098, alone or with other treatments, for adults with advanced solid tumors that have spread or cannot be removed. It may be an option if you have already tried standard treatments or if they are not suitable for you.

RET-targeting drug study for advanced cancers with RET changes

This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.

Test drug tulmimetostat for advanced cancers and lymphomas

This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.

Testing a new drug for breast cancer and other solid tumors

This trial tests a new oral drug (BGB-43395) alone or with other treatments for people with advanced breast cancer or other solid tumors that depend on CDK4. It aims to find safe doses and see if the drug helps shrink tumors or slow growth.

SA53-OS for advanced solid tumors

This trial tests an experimental drug (SA53-OS) for people with advanced solid tumors or certain lymphomas whose tumors have a normal p53 gene. The goal is to see if it is safe and helps shrink or slow the cancer.

Testing a new drug for advanced solid tumors

This trial tests ATX-295, a daily pill that blocks a protein called KIF18A, in people with advanced solid tumors, including ovarian cancer. It is for those whose cancer has grown after standard treatments or who cannot have standard therapy.

AI-081 for advanced solid tumors

This trial tests a new drug called AI-081 that targets the immune system and tumor blood vessels. It is for people with advanced solid tumors who have not responded to other treatments or cannot take them.

New drug APR-1051 for advanced solid tumors

This trial tests a new drug called APR-1051 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this drug is safe and effective.

BL-M07D1 for HER2-positive or HER2-low breast cancer

This Phase 1 study tests BL-M07D1, a new investigational medicine, in people with HER2-positive or HER2-low breast cancer (and other solid tumors) that can’t be operated on or has spread. It aims to find a safe dose and learn how well the treatment may work based on HER2 levels in tumor tissue.

Study of VVD-133214 for advanced solid tumors

This trial tests an experimental drug called VVD-133214, alone or with other medicines, in people with advanced solid tumors that have specific DNA repair problems (MSI-H/dMMR). The goal is to see if it is safe and effective.

Testing SHR-4610 for advanced solid tumors

This trial tests a new drug called SHR-4610 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective, and may be an option if you have a measurable tumor and are generally in good health.

Study of TUB-030 for advanced solid tumors

This trial tests a new drug called TUB-030 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.

Experimental drug CR-001 for advanced solid tumors

This trial tests an experimental drug called CR-001 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if CR-001 can slow or stop tumor growth.

Study of BG-75202 for advanced solid tumors

This trial tests a new drug called BG-75202, alone or with other drugs, for people with advanced breast cancer or other solid tumors that have stopped responding to standard treatments. It may offer a new option when other treatments have failed.

Testing CS5007 for Advanced Solid Tumors

This is an early-stage study testing a new drug called CS5007 in people with advanced cancer that cannot be surgically removed. The goal is to understand how safe the drug is and how well it works.

Testing GW01-200 tablets in advanced cancer patients

This is an early-stage trial testing a new drug called GW01-200 in people with advanced solid tumors or blood cancers that have gotten worse despite standard treatment. The study aims to find the right dose and see how well the drug works and is tolerated.

Study of a new drug (OTP-01) for advanced solid tumors

This trial is testing a new drug called OTP-01 that targets two proteins (PD-1 and VEGFR2) to help your immune system fight cancer and stop tumors from growing. It is for people with advanced solid tumors that have not responded to or cannot have standard treatments.

Study of GS-0201 alone and combined for advanced solid tumors

This trial tests a new drug called GS-0201, either by itself or with other treatments, for people with advanced solid tumors. The goal is to see if it is safe and helpful.